Global Biopharmaceutical Fermentation Systems Market is segmented By Product (Upstream Products, Downstream Products), By Application (Monoclonal Antibodies, Recombinant Proteins, Antibiotics, Probiotics), By End-User (Biopharmaceutical Companies, Contract Manufacturing Organizations, Contract Research Organizations, Academic Research Institutes, Food Industry), By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Biopharmaceutical Fermentation Systems Market Overview
The global biopharmaceutical fermentation systems market is estimated to reach at a high CAGR of 5,9% during the forecast period 2024-2031.
Biopharmaceutical fermentation systems can be defined as the process of incubating microorganisms within an enclosed tank or a fermenter under controlled conditions of aeration, agitation, temperature, and pH. Bacteria are used as the basis of fermentation processes. Chemical APIs that rely solely on microorganisms have fermentation as the only route to produce it.
Source: DataM Intelligence Analysis (2020)
Biopharmaceutical Fermentation Systems Market Dynamics
The biopharmaceutical fermentation systems market growth is driven by the increased usage of fermentation-derived products in various industries across the globe due to their natural structure, low cost, and better output. Moreover, the rise in research and developmental activities in different fields of fermentation technology, rise in awareness about products, and launch of new products are the factors expected to drive the market shortly.
Increasing innovations in the biotechnology sector and growing research and development of innovative novel formulations is expected to drive the growth in the forecast period
Technological advancements in bioproduction and genetically engineered microbial strains contribute to the high yield of microbial-based biopharmaceutical production. The downstream processing helps to find extensive use in the biotechnology sector to isolate and purify biological products. Therefore the isolation of biological products has thus helped the overall pharmaceutical industry to make strides.
There is also a considerable increase in the sales of biotechnology products that helps in the market's growth. Consequently, continual innovations in the biotechnology sector can increase market growth over the forecast period. For instance, in September 2019, National Aluminium Company Limited (NALCO) has launched Aluminium Alloy 1200 (AA 1200), adding one more downstream product to its existing product range. This alloy is similar to alloy AA 1100 and has a wide application in manufacturing LED lamp caps. In addition, the rise in the utilization of downstream processing techniques for the development of COVID-19 vaccines is a significant factor driving the market. In February 2021, Rentschler Biopharma, a Germany-based contract development and manufacturing organization (CDMO), announced to start commercial manufacture, formulation, and downstream processing of CVnCoV COVID-19 candidate vaccine by CureVac. Similarly, Bayer also announced to manufacture 160 million doses of CVnCoV in 2022.
Moreover, a few pharmaceutical organizations are occupied with innovative work of imaginative new plans and natural medications to meet the neglected helpful needs. For example, Biocon, India's biggest development drove, completely incorporated biopharmaceutical organization which positions among top three biosimilar worldwide players for insulin, has popularized the rh-insulin (recombinant human insulin) through Pichia maturation innovation. This is the major factor that boosts the growth of the global biopharmaceutical fermentation systems market.
Lack of awareness and trained professionals are likely to hamper the market growth
However, a lack of awareness and trained professionals in the field for biopharmaceutical fermentation systems might hamper the overall growth of the market. Moreover, introducing more advanced technologies to upgrade production, allow massive production units, and improve product quality approaches as profitable opportunities.
COVID-19 Impact on Biopharmaceutical Fermentation Systems Market
With the outbreak of COVID-19, the healthcare sector is adopting new technology that can help hospitals overcome the current pandemic and future medical emergencies. Owing to the growing adoption of new tools and technologies, the global biopharmaceutical fermentation systems market is projected to grow substantially during the coming years. COVID-19 has become a global pandemic and consumed more than a million lives. This has stimulated healthcare companies are developing innovative tools and technologies that can help doctors and medical officers to overcome present and future medical emergencies. For instance, In February 2021, Rentschler Biopharma; Germany-based contract development and manufacturing organization (CDMO) announced to start commercial manufacture, formulation, and downstream processing of CVnCoV COVID-19 candidate vaccine by CureVac. Similarly, Bayer also announced to manufacture 160 million doses of CVnCoV in 2022. Owing to this, the global biopharmaceutical fermentation systems market is projected to grow exponentially in the coming years.
Biopharmaceutical Fermentation Systems Market Segment Analysis
The downstream products segment is expected to hold the largest share in this market segment
Downstream processing refers to the recovery and the purification of biosynthetic products, particularly pharmaceuticals, from natural sources such as animal or plant tissue or fermentation broth, including the recycling of salvageable components and the proper treatment and disposal of waste.
Single-use chromatography and filtration systems are considered the gold standards in downstream bioprocessing. Hence companies are engaging in business development strategies such as acquisition, merger, and agreement for expanding their chromatography portfolio.
For instance, in October 2020, Repligen Corporation entered into a definitive agreement to acquire ARTeSYN Biosolutions. ARTeSYN Biosolutions is an established provider of single-use filtration and chromatography systems. The company also offers a wide range of single-use systems for continuous manufacturing and media/buffer preparation workflows. Similarly, in April 2020, Sartorius AG acquired Danaher Corporation’s chromatography hardware and resins, particle validation standards and microcarriers, and single-use tangential flow filtration business. This acquisition will help the company to expand its downstream processing offerings for chromatography systems.
The monoclonal antibodies segment is expected to hold the largest share in this market segment
The successful use of monoclonal antibodies and antibody derivatives in therapeutics is the major driver for the rapid growth of the studied segment. The therapeutic applications of monoclonal antibodies include cancer, rheumatoid arthritis, multiple sclerosis, and cardiovascular diseases, among others.
The recent COVID-19 outbreak has been creating a huge burden on healthcare systems. Researchers across the world are continuously making efforts to cope with this rising burden. Thus, the demand for monoclonal antibodies targeting COVID-19 is likely to exceed. For instance, in July 2020, an anti-CD6 IgG1 monoclonal antibody named Itolizumab (ALZUMAb), from Biocon Ltd, India was approved by the Drugs Controller General of India (DCGI) for the emergency treatment of cytokine release syndrome in acute respiratory distress syndrome patients infected with COVID-19.
Additionally, the growing FDA approvals and new product launches for various indications are expected to drive the segment. For instance, in January 2021, Cytiva launched HiScreen Fibro PrismA for the process development and purification of monoclonal antibodies (mAb). The product features a fiber-based Protein A platform which enables a 20-fold increase in productivity. In March 2019, the US FDA approved Pfizer’s oncology biosimilar, TRAZIMERA, a monoclonal antibody biosimilar to the originator biologic medicine, Herceptin. Thus, the monoclonal antibodies segment is anticipated to witness significant growth over the forecast period due to the factors mentioned above.
Source: DataM Intelligence Analysis (2020)
Biopharmaceutical Fermentation Systems Market Geographical Share
North America region holds the largest market share of the global biopharmaceutical fermentation systems market
North America is projected to hold the largest market share owing to government support for promoting bioprocess technologies, rising medical expenditure, and developed healthcare infrastructure. In addition, the region has witnessed major collaborative activities with healthcare giants that are extensively investing in the R&D of biopharmaceuticals and vaccines.
In addition, key players operating in the biopharmaceutical fermentation systems are expanding their foothold in this region. For instance, in December 2020, Thermo Fisher Scientific Inc. announced further expansion in Europe and North America for the commercial manufacturing of medicines, vaccines, and therapies. The expansion added 15 development and cGMP commercial production lines, leveraging the company’s robust quality standards for supporting a range of manufacturing capabilities.
Moreover, according to the Pharmaceutical Research and Manufacturers Association (PhRMA), in 2018, more than 4.7 million people worked in the US biopharmaceutical industry across a broad spectrum of occupations, including scientific research, technical support, and manufacturing. Additionally, in March 2020, Thermo Fisher Scientific Inc. invested nearly USD 475 million as a biopharma investment in the expansion of biologics, cell and gene therapy, and drug product development and to increase its commercial capabilities globally. Thus, given the aforementioned factors, the studied market is expected to propel significantly over the forecast period in North America.
Source: DataM Intelligence Analysis (2020)
Biopharmaceutical Fermentation Systems Market Competitive Landscape
The global biopharmaceutical fermentation systems market is highly competitive with the presence of global companies. Some of the key players which are contributing to the growth of the market include Corning, Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Sartorius StedimBiotech, Merck KGaA (Merck Millipore), Eppendorf AG, 3M Company., Nova Biomedicals, Lonza, and Repligen Corporation. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market. For Instance, in June 2020, Corning Incorporated launched the Corning X-SERIES cell processing platform. The X-SERIES products include X-LAB System, X-WASH System, and X-MINI Selection Kit for efficient cell separation and purification.
Biopharmaceutical Fermentation Systems Market Key Companies to Watch
Sartorius StedimBiotech
Overview: Sartorius Stedim Biotech is a leading partner in the biopharma industry. In 2007, Sartorius AG merged its Biotechnology Division with Stedim, creating Sartorius Stedim Biotech, headquartered in Aubagne, France. It has a worldwide presence, with manufacturing, sales and R&D sites in more than 20 countries in Europe, North America and Asia. More than 6,200 employees across the globe focus on single-use technologies and added-value services to meet the rapidly changing technology requirements of the industry it serves.
Product Portfolio: The key product categories are cell cultivation, fermentation, filtration, purification, and fluid management.
Products: Multi-Parallel Bioreactors, Benchtop Bioreactors, Single-Use Bioreactors, Stainless Steel Bioreactors, Cell Culture Bioreactors, Microbial Bioreactors, Software Apps for Bioreactors.
Key Developments: On October 21, 2019, Sartorius Stedim Biotech launches the new Sartocheck 5 Plus Filter Tester. Designed for use in downstream processing, this new integrity tester is the latest development in the established line of Sartocheck units already recognized throughout the pharmaceutical industry.
Why Purchase the Report?
- Visualize the composition of the biopharmaceutical fermentation systems market segmentation by product, application, end-user and region highlighting the key commercial assets and players.
- Identify commercial opportunities in the biopharmaceutical fermentation systems market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of biopharmaceutical fermentation systems market-level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players.
The global biopharmaceutical fermentation systems market report would provide access to an approx. 40+ market data table, 45+ figures and 180 pages.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers